Drugs acting on the nervous system

Dextroamphetamine (American English) or dexamfetamine (Commonwealth English) is a potent central nervous system (CNS) stimulant and amphetamine enantiomer that is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

Melatonin, chemically N-acetyl-5-methoxy tryptamine, is a substance found in animals, plants, fungi, and bacteria.

Amphetamine (contracted from alpha‑methylphenethylamine) is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity.

Levoamphetamine, also known as levamfetamine (INN), (R)-amphetamine, (−)-amphetamine, and L-amphetamine, is a central nervous system (CNS) stimulant known to increase wakefulness and concentration in association with decreased appetite and fatigue.

Metadoxine, also known as pyridoxine-pyrrolidone carboxylate, is a drug used to treat chronic and acute alcohol intoxication.

EMA401 is a new drug under development for the treatment of peripheral neuropathic pain.

4-Hydroxy-4-methylpentanoic acid (UMB68) is a tertiary alcohol, similar in structure to the drug GHB.

Lisdexamfetamine (contracted from L-lysine-dextroamphetamine) is a central nervous system (CNS) stimulant and dextroamphetamine prodrug of the phenethylamine class and amphetamine class that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder.

Octodrine is a stimulant drug whose pharmacology was briefly studied in the early 1950s.

Hopantenic acid (homopantothenic acid), also known as N-pantoyl-GABA, is a central nervous system depressant.

Tafamidis (INN, or Fx-1006A, trade name Vyndaqel) is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease.

Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS).

Org 25935 (SCH 900435) is a synthetic drug developed by Organon International, which acts as a selective inhibitor of the glycine transporter GlyT-1.

GSK2606414 is a drug which is the first selective inhibitor discovered for the enzyme protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), which is involved in various processes relating to cancer and neurodegenerative disorders.

Adderall is a combination drug containing salts of the two enantiomers of amphetamine, a central nervous system (CNS) stimulant of the phenethylamine class.

Arimoclomol (INN; originally codenamed BRX-345, which is a citrate salt formulation of BRX-220) is an experimental drug developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California.